Studying Pain Measurement and Treatment Effects in Children with Juvenile Arthritis, Lupus, or Fibromyalgia

What this Trial Is About

Researchers are investigating a new way to measure pain and the effects of treatment in three groups of children with rheumatologic conditions Juvenile Idiopathic Arthritis JIA, Systemic Lupus Erythematosus SLE, and Fibromyalgia FM. This study is observational and aims to develop an objective, physiological endpoint to better assess pain and treatment response, which could improve patient outcomes by reducing the need for trial-and-error treatments. Participants in this study will not receive any new treatments as part of the research. Instead, the study will observe patients aged 5 to 21 who have a confirmed diagnosis of JIA, SLE, or FM. Data will be collected at the start of the study and during their routine clinical visits over a one-year period. The focus is on characterizing a nociceptive index, which measures pain signals, to evaluate its potential as an objective marker of treatment effects. During the year-long follow-up, participants will undergo baseline and periodic assessments aligned with their standard care visits. These evaluations will include measurements related to the nociceptive index to monitor pain and response to ongoing treatments. The study aims to gather data to support the use of this index as a reliable tool for assessing pain and treatment effects in pediatric rheumatology patients.

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions